Emerging evidence also shows that intrinsic factors, such as altered metabolism, autophagy [97], cancer stem cells (CSCs) [98], and epithelial–mesenchymal transition (EMT) [99], are associated with poor outcomes despite anti-EGFR mAb treatment. The gene discussed is EGFR; the disease is cancer.